Results 71 to 80 of about 131 (88)

EE562 Cost-Effectiveness of the Dengue Vaccine TAK-003 in Thailand

Value in Health, 2023
J. Shen, E. Kharitonova, S. Biswal, M. Sharma, S. Aballea, A. Tytuła, J. Zawieja, P. Towle, R. Hanley, S. Rungmaitree   +9 more
openaire   +1 more source

Safety signal detected: Anaphylaxis after attenuated dengue vaccine (TAK-003) – Brazil, march 1, 2023-march 11, 2024

Vaccine
The aim was to describe cases of anaphylaxis following the Attenuated Dengue Vaccine (TAK-003) in Brazil, from March 1, 2023, to March 11, 2024. A descriptive study of anaphylaxis cases following TAK-003 was conducted, as reported in the National System of Surveillance of Adverse Events Following Immunization (AEFI).
Jadher, Percio, Carla Dinamerica, Kobayashi, Roberta Mendes Abreu, Silva, Ana Karolina Barreto Berselli, Marinho, Leon, Capovilla, Paulo Henrique Santos, Andrade, Martha Elizabeth Brasil, da Nóbrega, Cibelle Mendes, Cabral, Monica Brauner, de Moraes, Guilherme Loureiro, Werneck, Eder Gatti, Fernandes   +10 more
openaire   +2 more sources

Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate

Clinical Infectious Diseases, 2023
Martina Rauscher, Rauscher Martina
exaly  

Protocol Systematic review of health economic evaluation studies of TAK-003 and CYD-TDV

Title: Economic Evaluation of Dengue Vaccines Approved in Brazil: A Systematic Review Background: The application of Health Technology Assessment (HTA) in healthcare is essential as technological advancements and demands on health systems continue to grow (Nemzoff et al., 2023). Dengue, a major infectious disease in Brazil, significantly contributes to
openaire   +1 more source

EPH47 Modeling the Impact of the Vaccine Candidate TAK-003 on the Incidence of Dengue in French Overseas Territories

Value in Health, 2023
A. Nucit, R. Moreau, M. Massetti, C. Strub, E. Kharitonova, A. Tytula, J. Zawieja, H. Leleu, J. Shen   +8 more
openaire   +1 more source

Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination

Journal of Infectious Diseases, 2022
Eduardo López-Medina, Xavier Sáez-Llorens, Charissa Borja-Tabora   +2 more
exaly  

TAK-003 Dengue Vaccine Clinical Experience: An Integrated Safety Analysis by Baseline Dengue Serostatus

2023
Patel, Sanjay S, Rauscher, Martina, Mandaric, Sanja, Pang, Hang   +3 more
openaire   +1 more source

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)

Clinical Infectious Diseases, 2022
Xavier Sáez-Llorens, Eduardo López-Medina, Charissa Borja-Tabora   +2 more
exaly  

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country

Vaccine, 2023
Paul Collini, ZENAIDA Mojares, Martina Rauscher   +2 more
exaly  

EE528 Cost-Effectiveness Analysis of the TAK-003 Dengue Vaccine Introduction in Argentina

Value in Health
A Uruena, N Giglio, PV Micone, S Rapaport, P Towle, D Shih, J Langer, A Carbone   +7 more
openaire   +1 more source